Pairing Diagnostics with Therapeutics: KineMed to Present Biomarker Solutions for Personalized Medicine at the 2012 BIO Investor Forum

David Fineman, KineMed, Inc.’s President and CEO will present at the 2012 BIO Investor Forum on Wednesday, October 10th

EMERYVILLE, Calif.--(BUSINESS WIRE)-- KineMed, Inc. ( announced today that David Fineman, KineMed, Inc.’s President and CEO will present at the 2012 BIO Investor Forum on Wednesday, October 10th at 11:00 AM PST at the Palace Hotel in San Francisco, CA.

In a talk entitled “Pairing Diagnostics with Therapeutics: Biomarker Solutions for Personalized Medicine”, Mr. Fineman will share recent developments and breakthrough results from KineMed’s powerful kinetic biomarker platform for interrogating the dynamic behavior of the human proteome and lipidome, and discuss how KineMed’s exquisitely targeted translational biomarker repertoire is being used as the first functionally interpretable and clinically predictive systems biology platform that can be translated directly into humans.

“The timing could not be better for a revolution in biomarker technology,” commented Mr. Fineman, “The rapid, inexorable shift of pharmaceutical development and patient care towards the “Personalized Medicine” model means that drugs must be paired with diagnostic biomarkers to enable the right drug to be selected for the right patient at the right time. This requires better targeting of disease subclasses: patient-specific diagnostics, as well as more disease subset-specific therapeutics. KineMed’s dynamic signatures translate directly into humans and by virtue of being functionally interpretable and much closer to phenotype than other “–omics” technologies, our measurements offer perhaps the most clinically predictive class of biomarkers yet developed, enabling greater public health benefits and better reimbursement rates for commercial providers.”

A webcast of the presentation will be available on Wednesday, October 10th at 12:00 PM PST, one hour after Mr. Fineman’s live presentation via KineMed’s website at

About KineMed, Inc.

KineMed, Inc., based in Emeryville, CA, is a drug and disease diagnostic developer, serving pharmaceutical clients and foundations with decision-critical information that accelerates, guides and de-risks drug development, to reduce cost and avoid attrition. KineMed is a partner of choice for drug developers seeking to develop the next generation of medicines that target the underlying causes rather than expressed symptoms of disease and is a field leader in pairing drugs with diagnostic biomarkers that offer “Yes/No” answers to critical patient management questions: Is this the right drug? Is the drug working?

KineMed’s biomarkers are qualitatively and quantitatively different in the answers that they give, compared with other molecular diagnostics, because they are based on kinetic measurements - active measures that compare the rate of biochemical changes between healthy and disease states in a living animal or human. The company’s unique, patented isotopic tracer technology tracks dynamic changes in key biochemical pathways that identify the complex biological processes underlying disease to predict clinical outcome. KineMed’s biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, metabolic, cardiovascular disease, and cancer.

KineMed’s platform addresses key industry needs:

  • Focus on causes rather than symptoms: Generating pivotal knowledge for developing novel therapeutics that are differentiated by targeting underlying biochemical causes and mode of action
  • Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context
  • Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
  • Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine

In addition to assisting clients, KineMed also has an active pipeline of therapeutics and diagnostics in development.

KineMed is seeking further broad collaborations with biotechnology, pharmaceutical, CRO, histopathology, diagnostics and medical instrument partners.

For more information about KineMed, please visit:

KineMed Inc.
Ravi Kiron, Ph.D., 510-655-6525 ext. 105
Chief Business Officer

Source: KineMed, Inc.